Analyst consensus rating
C4 Therapeutics Analyst Rating: Strong Buy
Direct answer
C4 Therapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.50.
Forecast evidence checked November 10, 2026.
Get free C4 Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.00
- Average price target
- $12.50
- High price target
- $30.00
- Low price target
- $6.00
- Low target gap
- +100.3%
- Target upside
- +317.4%
- High target gap
- +901.7%
- Target range width
- 801.3%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for C4 Therapeutics?
C4 Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $12.50.
How far are C4 Therapeutics's low and high targets from the recorded price?
The low target implies +100.3%, while the high target implies +901.7%.
How many analysts are included in C4 Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is C4 Therapeutics's target upside or downside calculated?
The average target of $12.50 is divided by the recorded price of $3.00, then one is subtracted to produce +317.4%. This does not guarantee a future return.
When was C4 Therapeutics's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.